Drug Database
LE

leuprolide (Lutrate)

✓ Approved

GP Pharm · GNRHR · 小分子

什么是 leuprolide?

leuprolide 是一种小分子,由GP Pharm研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Lutrate
公司GP Pharm
药物类别小分子, 多肽类
分子靶点GNRHR
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

leuprolide 作用于 1 个分子靶点:

GNRHRgonadotropin releasing hormone receptor (HH7, GRHR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

leuprolide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer✓ Approved

相关研究文献

PubMedCureus2026-11-13

A Rare Association of Bladder Endometriosis, Unicornuate Uterus, and Hematometra: A Case Report.

Kumar Pranesh K PK, Yadav Vamshi C VC, Singh Davneet D, Thirukovela Jagadeeshwar J et al.

Endometriosis involving the urinary tract is uncommon, with the urinary bladder being the most frequently affected site. Its nonspecific urinary manifestations may result in delayed diagnosis. Congenital Müllerian anomalies, particularly a unicornuate uterus with a noncommunicating functional rudimentary horn, may be associated with hematometra and endometriosis secondary to obstructed menstrual outflow and retrograde menstruation. We report an unusual coexistence of bladder endometriosis, a right unicornuate uterus with a noncommunicating left rudimentary cavity, and hematometra in a 22-year-old nulliparous woman who presented with a one-year history of cyclical dysuria, hematuria, and dyspareunia. She had regular menstrual cycles associated with dysmenorrhea and had attempted conception without success. Pelvic magnetic resonance imaging demonstrated a right hemi-uterus measuring approximately 7 × 3 × 2.5 cm and a separate left-sided endometrial cavity measuring 4.1 × 3.5 × 4.2 cm, which did not communicate with the uterus and was distended with hematometra. An ill-defined T2 hypointense lesion measuring 3.4 × 2.3 × 3 cm with T1 hyperintense foci was centered in the vesicouterine pouch, extending posteriorly into the lower uterine segment and cervix and anteriorly into the bladder wall with intraluminal extension. Thickening of the proximal bilateral round ligaments was also noted, with the overall appearance suggestive of deep pelvic endometriosis. Cystoscopy showed multiple reddish-brown cystic lesions involving the lateral and posterior walls of the urinary bladder. Near-complete transurethral resection of the bladder lesions was performed, along with laparoscopic drainage and partial excision of the rudimentary horn. Histopathological examination of the resected bladder lesions confirmed bladder endometriosis. Postoperatively, the patient was started on leuprolide acetate and remained symptom-free at six-month follow-up. This case highlights the importance of considering bladder endometriosis in young women presenting with cyclical urinary symptoms and demonstrates the value of magnetic resonance imaging in delineating Müllerian anomalies, hematometra, and the extent of deep pelvic endometriosis. The coexistence of extensive bladder endometriosis with a unicornuate uterus and hematometra underscores the importance of coordinated urological and gynecological management.

PMID 43022152
阅读全文 →
PubMedAsian journal of pharmaceutical sciences2026-11-08

From molecular bridge to macro-encapsulation: Unraveling the HEPES-porosity synergy for ultra-high peptide loading in PLGA microspheres.

Bai Jiahui J, Wang Shan S, Li Ke K, Cui Jingyu J et al.

The clinical translation of long-acting peptide-loaded microspheres is often hampered by low and unpredictable encapsulation efficiency (EE), stemming from the complex interplay among formulation parameters. This study clarified these interactions by establishing a holistic, mechanism-guided framework that integrated polymer chemistry, matrix microstructure, and the incubation microenvironment. Using leuprolide acetate as a model peptide, we systematically deconstructed the key determinants of EE in a self-healing poly(lactic-co-glycolic acid) (PLGA) microsphere system. We found that the terminal carboxyl content of PLGA was a major determinant of peptide-polymer binding affinity, while the engineered pore architecture balanced peptide accessibility and retention and modulated loading-associated peptide-polymer interactions. Crucially, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) provided a more favorable loading environment than phosphate-buffered saline or Tris(hydroxymethyl)aminomethane hydrochloride and promoted peptide-PLGA association. Convergent experimental and simulation evidence supported a proposed HEPES-mediated non-covalent ternary association among leuprolide, HEPES, and PLGA. Optimization of the HEPES concentration and self-healing conditions further enhanced peptide-polymer association and encapsulation. Applying these findings, we fabricated optimized leuprolide-loaded microspheres with an EE of 96.44% and a drug loading of 9.64%, which were higher than the reported EE and drug-loading values for Lupron DepotⓇ. The applicability of this formulation framework beyond the leuprolide acetate formulation was further supported by the high EEs achieved for two additional cationic peptides, triptorelin acetate (90.26%) and octreotide acetate (91.04%). This work provides a rational, multi-parameter formulation framework for improving the encapsulation of selected cationic peptides in self-healing PLGA microspheres by integrating mechanistic evidence with pharmaceutical formulation design.

PMID 42997591
阅读全文 →
PubMedPhysiology & behavior2026-10-30

Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.

Gutiérrez-Esparza Brenda Lizeth BL, González-Torres Marina Liliana ML, Quintanar-Stephano Andrés A, Calderón-Vallejo Denisse D et al.

Patients with hepatic encephalopathy (HE) experience both cognitive and motor coordination alterations, which lead to a decrease in quality of life. During the progression of this disease, the cerebellum is one of the most affected brain regions due to elevated blood ammonia levels that cause neuronal damage and contribute to motor dysfunction. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) receptor agonist, has demonstrated neurotrophic effects in various regions of the central nervous system. Therefore, this study evaluated the potential neurotrophic effect of LA on the cerebellum in a rat model of HE induced by portocaval anastomosis (PCA). For the experimental design, male Wistar rats were divided into three groups: SHAM, PCA with saline solution (PCA+SS), and PCA treated with LA (PCA+LA). Motor function was assessed using rotarod and open field tests. Histological assessment of the cerebellum was performed using H&E staining, while immunoreactivity of the apoptotic markers caspase-8 and caspase-3 were analyzed to evaluate apoptosis. In addition, the expression of proteins associated with neuronal integrity and recovery, including NF200, neurabin II, and BDNF, were examined. The results showed that LA administration significantly improved motor coordination. Treated animals exhibited reduced neuronal loss in the Purkinje and granular layers, decreased activation of caspase-8 and caspase-3, and increased expression of neurabin II and BDNF. Collectively, these findings indicate that LA has therapeutic potential to attenuate cerebellar neuronal damage and promote functional recovery during HE.

PMID 42962871
阅读全文 →
PubMedReproductive biology2026-10-30

Leuprolide acetate improves ovarian indices but does not restore uterine morphometry in obese Zucker rats.

Martínez-García Natalia N, Trujillo-Hernández Angélica A, Cortés Carmen C, Eguibar José Ramón JR

Obesity is associated with disrupted estrous cyclicity, impaired follicular development, and altered uterine responses. Leuprolide acetate (LA), a gonadotropin-releasing hormone agonist, produces time-dependent effects on the reproductive axis; however, its actions under severe obesity remain poorly defined. This study evaluated the effects of LA on metabolic parameters, estrous cyclicity, ovarian morphology, and uterine morphometry in obese Zucker rats. Thirty-six adult female rats were used: normal-weight Long-Evans (LE) and obese Zucker (OZ) rats were assigned to untreated control, vehicle, or LA-treated groups (n = 6/group). LA was administered subcutaneously at 2.5 μg/rat/day for 21 consecutive days. Estrous cyclicity was evaluated before and during treatment, and metabolic, ovarian, and uterine outcomes were assessed after treatment. Obese Zucker rats exhibited greater adiposity, metabolic alterations, prolonged and disrupted estrous cycles, impaired follicular development, increased follicular atresia, fewer corpora lutea, and altered uterine morphometry. LA produced condition-dependent reproductive responses. In obese rats, LA shortened the prolonged estrous cycle and shifted estrous-stage distribution toward the pattern observed in normal-weight animals. LA also increased healthy, developing, antral, and preovulatory follicles, markedly increased corpora lutea, and reduced follicular atresia and cystic structures. In contrast, LA produced predominantly suppressive follicular and estrous-cycle changes in normal-weight rats. LA markedly reduced total cholesterol in obese rats without modifying serum glucose, whereas no condition-specific treatment effect on triglycerides was detected. At the uterine level, LA reduced uterine diameter in obese rats but did not modify endometrial thickness. These findings indicate that LA produces markedly different reproductive responses according to the metabolic and reproductive context, improving several follicular and luteal histomorphometric indices in obese Zucker rats without a parallel restoration of uterine morphometry.

PMID 42962532
阅读全文 →
PubMedFrontiers in endocrinology2026-10-29

Gonadotropin-releasing hormone antagonists versus agonists for endometriosis: a systematic review and meta-analysis of randomized controlled trials.

Liu Tianmeng T, Cai Yuhong Y, Li Mingyang M, Cai Suqing S et al.

Endometriosis is a chronic estrogen-dependent inflammatory disease requiring individualized long-term hormonal management. Gonadotropin-releasing hormone agonists (GnRH-a) effectively suppress ovarian function but may induce hypoestrogenic adverse effects, whereas oral gonadotropin-releasing hormone antagonists (GnRH-ant) offer rapid, reversible suppression with reduced hormonal fluctuation. However, their comparative efficacy and safety remain unclear. We performed a systematic review and meta-analysis of randomized controlled trials comparing GnRH-ant with leuprolide-based GnRH-a for the treatment of endometriosis, assessing symptom relief, pelvic signs, bone mineral density (BMD), quality of life, and hormonal outcomes. Five randomized controlled trials were included. Compared with GnRH-ant, GnRH-a yielded greater improvements in dysmenorrhea (standardized mean difference (SMD) = 0.69, 95% CI: 0.48-0.91), nonmenstrual pelvic pain (NMPP) (SMD = 0.33, 95% CI: 0.16-0.50), overall pelvic pain (OPP) (SMD = 0.25, 95% CI: 0.13-0.38), and dyspareunia (SMD = 0.14, 95% CI: 0.02-0.26). GnRH-a was also associated with better outcomes in pelvic tenderness, Douglas pouch induration scores, peak pain severity, analgesic requirements, and menstrual blood loss. Subgroup analysis suggested a more pronounced analgesic benefit of GnRH-a after 12 weeks of treatment. In contrast, GnRH-ant resulted in significantly less BMD reduction (SMD = 0.64, 95% CI: 0.39-0.89), a stronger bone-sparing effect at 24 weeks. No significant differences were observed in most quality-of-life domains. Leuprolide-based GnRH-a provides superior symptom control, whereas GnRH-ant offers less decline in BMD and reversible ovarian suppression, but differences among individual antagonists should be considered. Treatment selection should be individualized based on symptom severity, bone health, and fertility goals. Long-term head-to-head trials are warranted. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261289010, identifier CRD420261289010.

PMID 42953143
阅读全文 →
PubMedAnnals of African medicine2026-10-27

A Systematic Review of Elagolix for the Management of Endometriosis-associated Pain.

Aafreen Sana S, Haque Ekramul E, Kumar Tushar T

Endometriosis is a chronic, estrogen dependent condition affecting up to 10% of women of reproductive age, characterized by dysmenorrhea, dyspareunia, and nonmenstrual pelvic pain. Conventional treatments are often limited by inadequate efficacy or tolerability. Elagolix, an oral nonpeptide gonadotropin releasing hormone (GnRH) antagonist approved by the Food and Drug Administration in 2018, offers dose dependent estrogen suppression with rapid reversibility upon discontinuation. This systematic review synthesizes the current evidence on elagolix for the management of endometriosis associated pain. A comprehensive search was conducted across PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception to September 2024. Studies were screened per Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines and quality appraised using the a measurement tool to assess systematic reviews 2. (AMSTAR 2) checklist. From 103 identified records, 20 studies were included, encompassing Phase II/III randomized controlled trials, long term extension studies, systematic reviews, network meta analyses, real world data analyses, postmarketing safety reports, and cost effectiveness studies. Elagolix significantly reduced dysmenorrhea (up to ~75% responder rate), nonmenstrual pelvic pain (~55%-69%), and dyspareunia (~60%) compared to placebo, with benefits sustained at 12 months. Efficacy was dose dependent; higher doses yielded greater symptom relief but increased hypoestrogenic adverse effects, primarily hot flushes and decreased bone mineral density (BMD). BMD loss remained minimal (<2% annually) with add back estradiol/norethindrone acetate therapy. Network meta analyses demonstrated comparable or superior efficacy versus other oral GnRH antagonists. Elagolix was cost effective compared to leuprolide acetate in the US settings, and patients favored its oral administration. Elagolix represents an effective, patient centered therapeutic option for moderate to severe endometriosis associated pain, with a well characterized safety profile. Future research should address long term safety beyond 48 months, direct comparisons with first line hormonal therapies, and cost effectiveness in non US healthcare settings.

PMID 42937421
阅读全文 →

注册免费账户还可查看另外 2292 篇文献

免费注册查看全部文献 →

了解更多leuprolide